Compare GCT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | EVO |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | GCT | EVO |
|---|---|---|
| Price | $38.01 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $33.00 | $7.00 |
| AVG Volume (30 Days) | ★ 615.7K | 39.3K |
| Earning Date | 05-08-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.70 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $1,161,042,000.00 | N/A |
| Revenue This Year | $14.43 | $1.37 |
| Revenue Next Year | $6.78 | $10.05 |
| P/E Ratio | $36.50 | ★ N/A |
| Revenue Growth | ★ 64.96 | N/A |
| 52 Week Low | $20.71 | $1.95 |
| 52 Week High | $51.82 | $4.42 |
| Indicator | GCT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 24.34 |
| Support Level | $37.46 | N/A |
| Resistance Level | $43.64 | $3.36 |
| Average True Range (ATR) | 1.49 | 0.10 |
| MACD | 0.72 | -0.09 |
| Stochastic Oscillator | 84.18 | 4.08 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia with resellers in the U.S., Asia, and Europe to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price. It earns the majority of its revenue from the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.